Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2011

Open Access 01-12-2011 | Research

MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells

Authors: Moorthy P Ponnusamy, Parthasarathy Seshacharyulu, ArokiaPriyanka Vaz, Parama Dey, Surinder K Batra

Published in: Journal of Ovarian Research | Issue 1/2011

Login to get access

Abstract

Background

Recent evidence has suggested that the capability of cancer to grow, propagate and relapse after therapy is dependent on a small subset of the cell population within the tumor, called cancer stem cells. Therefore, this subpopulation of cells needs to be targeted with different approaches by identification of unique stem-cell specific target antigens. One of the well known tumor antigens is the epithelial cell mucin MUC4, which is aberrantly expressed in ovarian cancer as compared to the normal ovary and plays a pivotal role in the aggressiveness and metastasis of ovarian cancer cells. In the present study, we aimed to analyze the cancer stem cell population in MUC4 overexpressed ovarian cancer cells.

Methods

MUC4 was ectopically overexpressed in SKOV3 ovarian cancer cells. Western blot analysis was performed for MUC4, HER2, CD133, ALDH1 and Shh expression in MUC4 overexpressed cells. Confocal analysis of MUC4, HER2 and CD133 was also done in the MUC4 overexpressed cells. CD133 and Hoechst33342 dye staining was used to analyze the cancer stem cell population via FACS method in SKOV3-MUC4 cells.

Results

MUC4 overexpressed SKOV3 cells showed an increased expression of HER2 compared to control cells. MUC4 overexpression leads to increased (0.1%) side population (SP) and CD133-positive cancer stem cells compared to the control cells. Interestingly, the tumor sphere type circular colony formation was observed only in the MUC4 overexpressed ovarian cancer cells. Furthermore, the cancer stem cell marker CD133 was expressed along with MUC4 in the isolated circular colonies as analyzed by both confocal and western blot analysis. HER2 and cancer stem cell specific marker ALDH1 along with Shh, a self-renewal marker, showed increased expression in the isolated circular colonies compared to MUC4-transfected cells.

Conclusion

These studies demonstrate that MUC4 overexpression leads to an enriched ovarian cancer stem cell population either directly or indirectly through HER2. In future, this study would be helpful for MUC4-directed therapy for the ovarian cancer stem cell population.
Appendix
Available only for authorised users
Literature
1.
2.
Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5: 275–284. 10.1038/nrc1590PubMedCrossRef
3.
Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Buchler MW, Aubert JP, Batra SK: Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001, 7: 4033–4040.PubMed
4.
Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4: 45–60. 10.1038/nrc1251PubMedCrossRef
5.
Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK: Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 2006, 19: 1386–1394. 10.1038/modpathol.3800646PubMedCrossRef
6.
Giuntoli RL, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA: Mucin gene expression in ovarian cancers. Cancer Res 1998, 58: 5546–5550.PubMed
7.
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK: MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 2008, 68: 2065–2070. 10.1158/0008-5472.CAN-07-6041PubMedCentralPubMedCrossRef
8.
Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK: MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer 2008, 99: 520–526. 10.1038/sj.bjc.6604517PubMedCentralPubMedCrossRef
9.
Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P, Batra SK: MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene 2010, 29: 5741–5754. 10.1038/onc.2010.309PubMedCentralPubMedCrossRef
10.
Korkaya H, Paulson A, Iovino F, Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27: 6120–6130. 10.1038/onc.2008.207PubMedCentralPubMedCrossRef
11.
Engelmann K, Shen H, Finn OJ: MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008, 68: 2419–2426. 10.1158/0008-5472.CAN-07-2249PubMedCrossRef
12.
Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, Batra SK: Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 2007, 97: 345–357. 10.1038/sj.bjc.6603868PubMedCentralPubMedCrossRef
13.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006, 103: 11154–11159. 10.1073/pnas.0603672103PubMedCentralPubMedCrossRef
14.
Bunting KD: ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20: 11–20. 10.1002/stem.200011PubMedCrossRef
15.
Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K: The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002, 8: 22–28.PubMed
16.
Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133–1 and CD133–2 in ovarian cancer. Int J Gynecol Cancer 2008, 18: 506–514. 10.1111/j.1525-1438.2007.01056.xPubMedCrossRef
17.
Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27: 1749–1758. 10.1038/sj.onc.1210811PubMedCrossRef
18.
Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin Oncol 1998, 25: 281–304.PubMed
19.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59: 225–249. 10.3322/caac.20006PubMedCrossRef
20.
Wong AS, Auersperg N: Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 2003, 1: 70. 10.1186/1477-7827-1-70PubMedCentralPubMedCrossRef
21.
Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100: 3983–3988. 10.1073/pnas.0530291100PubMedCentralPubMedCrossRef
22.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65: 10946–10951. 10.1158/0008-5472.CAN-05-2018PubMedCrossRef
23.
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104: 10158–10163. 10.1073/pnas.0703478104PubMedCentralPubMedCrossRef
24.
Marsden CG, Wright MJ, Pochampally R, Rowan BG: Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 2009, 590: 363–375. 10.1007/978-1-60327-378-7_23PubMedCrossRef
25.
Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007, 11: 981–1011. 10.1111/j.1582-4934.2007.00088.xPubMedCentralPubMedCrossRef
26.
Boman F, Buisine MP, Wacrenier A, Querleu D, Aubert JP, Porchet N: Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study. J Pathol 2001, 193: 339–344. 10.1002/1096-9896(2000)9999:9999<::AID-PATH798>3.0.CO;2-9PubMedCrossRef
27.
Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK: Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004, 64: 622–630. 10.1158/0008-5472.CAN-03-2636PubMedCrossRef
28.
Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL: Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell 2006, 17: 2931–2941. 10.1091/mbc.E05-09-0895PubMedCentralPubMedCrossRef
Metadata
Title
MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells
Authors
Moorthy P Ponnusamy
Parthasarathy Seshacharyulu
ArokiaPriyanka Vaz
Parama Dey
Surinder K Batra
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2011
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-4-7

Other articles of this Issue 1/2011

Journal of Ovarian Research 1/2011 Go to the issue

Research

Accuracy of 64-multidetector computed tomography in diagnosis of adnexal tumors

Research

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

Research

A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil

Research

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

Research

Sphingosine-1 phosphate receptor (S1p1), a critical receptor controlling human lymphocyte trafficking, is expressed in hen and human ovaries and ovarian tumors

Research

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines